Effects of Salvia miltiorrhiza active compounds on placenta-mediated pregnancy complications

Front Cell Dev Biol. 2023 Jan 13:11:1034455. doi: 10.3389/fcell.2023.1034455. eCollection 2023.

Abstract

Placenta-mediated pregnancy complications (PMPCs), including preeclampsia (PE), fetal growth restriction (FGR), and recurrent spontaneous abortion (RSA), occur in approximately 5% of pregnancies and are caused by abnormal placenta development. The development of effective therapies for PMPCs is still challenging due to the complicated pathogenesis, such as disrupted vascular homeostasis and subsequent abnormal placentation. Synthetic drugs have been recommended for treating PMPCs; however, they tend to cause adverse reactions in the mother and fetus. Salvia miltiorrhiza (S. miltiorrhiza) has potential effects on PMPCs owing to its advantages in treating cardiovascular disorders. S. miltiorrhiza and its active compounds could attenuate the symptoms of PMPCs through anticoagulation, vasodilation, antioxidation, and endothelial protection. Thus, in this review, we summarize the literature and provide comprehensive insights on S. miltiorrhiza and its phytochemical constituents, pharmacological activities, and on PMPCs, which would be valuable to explore promising drugs.

Keywords: Salvia miltiorrhiza; active compounds; placental development; placental pregnancy complications; preeclampsia.

Publication types

  • Review

Grants and funding

This study was partly supported by the Guangzhou Science and Technology Program (No. 202102010129).